EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Risk Factors for the Development of BK Polyomavirus and Treatment Outcomes in Kidney Transplant Recipients: An 8‐Year Retrospective Cohort Study

Alyssa Pradhan, Melanie Wyld, Susan Wan, Rebecca Davis, Kushani Jayasinghe, Kate Wyburn

Nephrology · 2025-06 · 30 (6)

DOI: 10.1111/nep.70058 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background BKPyV‐DNAemia occurs in up to 30% of kidney transplant recipients (KTRs), with graft‐threatening BKPyV‐nephropathy in up to 10%. Risk factors for BKPyV‐DNAemia, BKPyV‐nephropathy, and associated graft loss are incompletely described. We sought to determine the prevalence, risk factors for, and long‐term impact of BKPyV‐DNAemia. Methods A single‐centre retrospective study of adult KTRs between 2010 and 2018. We used logistic regression to determine odds ratios (OR) of BKPyV‐DNAemia, and survival analysis to assess the impact of BKPyV‐DNAemia on graft and patient survival. Results Of 522 patients, 100 (19%) developed BKPyV‐DNAemia and 43 (8.2%) developed BKPyV‐nephropathy, resulting in the loss of two grafts. Factors associated with the development of BKPyV‐DNAemia were non‐Caucasian ethnicity (OR 1.76, CI 0.98–3.16), pre‐transplant diabetes (OR 2.06, CI 1.02–4.14) and HLA mismatch of 3/6 or 4/6 (OR 2.37, CI 1.06–5.56) and HLA mismatch of 5/6 and 6/6 (OR 2.53, CI 1.20–5.63). Additionally, a greater than 25 mg per day prednisolone dose following acute transplant and acute rejection in the first month post‐transplant was associated with an increased risk of BKPyV‐DNAemia (OR 3.06, CI 1.66–6.06 and OR 2.36, CI 1.16–4.75 respectively). Over a 10‐year follow‐up, the development of BKPyV‐DNAemia and BKPyV‐nephropathy was not associated with reduced graft or patient survival. Conclusion While BKPyV‐DNAemia and BKPyV‐nephropathy remain prevalent in KTR, there were low rates of associated graft loss and no demonstrable impact on long‐term graft or patient survival.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →